<?xml version="1.0" encoding="UTF-8"?>
<p>Corticosteroid (40 mg methylprednisolone once or twice per day) was administered to 11 patients within 24 hours of admission for a median 5 days (IQR, 4.5–5.0 days) (
 <xref rid="mja250577-fea-0003" ref-type="boxed-text">Box 3</xref>). Patients who received corticosteroid treatment had a higher maximum temperature on admission than patients who did not receive corticosteroid treatment (38.8°C [IQR, 38.2–39.0°C] 
 <italic>v</italic> 37.8°C [IQR, 37.0–38.1°C]; 
 <italic>P</italic> = 0.002), and more frequently reported clinical symptoms on admission, including myalgia or fatigue (11 of 11 [100%] 
 <italic>v</italic> 8 of 20 [40%]; 
 <italic>P</italic> = 0.004) and cough (10 of 11 [91%] 
 <italic>v</italic> 8 of 20 [40%]; 
 <italic>P</italic> = 0.018) (
 <xref rid="mja250577-fea-0001" ref-type="boxed-text">Box 1</xref>). Moreover, patients receiving corticosteroid treatment had higher median CRP levels (84.0 mg/L [IQR, 18.6–150 mg/L 
 <italic>v</italic> 18.7 mg/L [IQR, 4.77–29.6 mg/L; 
 <italic>P</italic> = 0.026) and lower median lymphocyte count (0.99 × 10
 <sup>9</sup>/L [IQR, 0.88–1.29 × 10
 <sup>9</sup>/L) 
 <italic>v</italic> 1.54 × 10
 <sup>9</sup>/L [IQR, 1.25–1.77 × 10
 <sup>9</sup>/L]; 
 <italic>P</italic> = 0.012) than patients who did not receive corticosteroid. bilateral involvement was more frequently evident on chest CT of these patients (11 of 11 [100%] 
 <italic>v</italic> 9 of 20 [45%]; 
 <italic>P</italic> = 0.009) (
 <xref rid="mja250577-sup-0001" ref-type="supplementary-material">Supporting Information</xref>).
</p>
